Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRAP-ES vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing c GMP levels.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (alone or in combination with other antihypertensives),Off-label: Heart failure (as adjunctive therapy in African American patients)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.
250 mg orally twice daily
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours in severe cases).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic via N-acetylation by N-acetyltransferase 2 (NAT2). Metabolites include hydralazine pyruvic acid hydrazone, acetylhydralazine, and others.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal (<10%).
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 87% bound to plasma proteins (primarily albumin).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 50-60% due to first-pass metabolism; Intravenous: 100%.
70-90% (oral); 100% (IV).
GFR 10-50 m L/min: Administer every 6-8 hours. GFR <10 m L/min: Administer every 8-12 hours.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use with caution, reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Oral/IV: 0.1-0.5 mg/kg/dose every 6 hours; max initial dose 25 mg/dose.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at 10-25 mg twice daily; titrate slowly due to increased risk of hypotension and electrolyte disturbances.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No FDA boxed warning for Hydralazine.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause drug-induced lupus erythematosus (especially in slow acetylators),May cause peripheral neuritis (pyridoxine deficiency),May cause tachycardia, angina, or myocardial infarction in patients with coronary artery disease,May cause hypotension and renal impairment,Monitor for signs of lupus and neuropathy
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to hydralazine,Mitral valve rheumatic heart disease,Coronary artery disease (due to reflex tachycardia)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Take with food to reduce gastrointestinal upset. Avoid high-tyramine foods if taking concomitant MAOIs, though hydralazine itself has no direct tyramine interaction. No specific food restrictions, but limit alcohol as it may exacerbate hypotension.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: No evidence of teratogenicity in human studies; animal studies show no fetal harm. Second and third trimesters: Associated with reduced placental perfusion and fetal growth restriction; risk of neonatal hypotension, hypoglycemia, and bradycardia if used near term.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Considered compatible with breastfeeding; monitor infant for hypotension and drowsiness.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Hypertension in pregnancy may require increased dosing due to increased volume of distribution and renal clearance; start with low doses and titrate based on blood pressure response; avoid severe hypotension to maintain placental perfusion.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Hydralazine, the active component, is a direct-acting vasodilator used for hypertension. It can cause a lupus-like syndrome, especially in slow acetylators. Monitor for tachycardia and fluid retention; consider concomitant beta-blocker and diuretic. Do not use as monotherapy for long-term management. Onset of action is rapid (15-20 min) IV, but oral bioavailability is variable (30-50%). Dose adjustments needed in renal impairment.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Report any joint pain, rash, fever, or unexplained bruising/bleeding.,May cause headaches or palpitations, especially early in therapy.,Avoid sudden discontinuation to prevent rebound hypertension.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRAP-ES vs ALDOCLOR-250, answered by our medical review team.
HYDRAP-ES is a Antihypertensive Combination that works by Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased systemic vascular resistance and reduced blood pressure. The exact molecular mechanism involves inhibition of inositol trisphosphate (IP3)-induced calcium release from the sarcoplasmic reticulum and activation of guanylate cyclase, increasing c GMP levels.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRAP-ES and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRAP-ES is: Oral: 25-50 mg twice daily, max 200 mg/day. IV: 10-20 mg every 4-6 hours as needed.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRAP-ES and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRAP-ES is classified as Category C. First trimester: No evidence of teratogenicity in human studies; animal studies show no fetal harm. Second and third trimesters: Associated with reduced placental perfusion and fet. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.